These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 6341126

  • 1. Abnormalities of GIP in spontaneous syndromes of obesity and diabetes in mice.
    Flatt PR, Bailey CJ, Kwasowski P, Swanston-Flatt SK, Marks V.
    Diabetes; 1983 May; 32(5):433-5. PubMed ID: 6341126
    [Abstract] [Full Text] [Related]

  • 2. Plasma immunoreactive gastric inhibitory polypeptide in obese hyperglycaemic (ob/ob) mice.
    Flatt PR, Bailey CJ, Kwasowski P, Page T, Marks V.
    J Endocrinol; 1984 Jun; 101(3):249-56. PubMed ID: 6374002
    [Abstract] [Full Text] [Related]

  • 3. Immunoreactive neurotensin in spontaneous syndromes of obesity and diabetes in mice.
    Sheppard MC, Bailey CJ, Flatt PR, Swanston-Flatt SK, Shennan KI.
    Acta Endocrinol (Copenh); 1985 Apr; 108(4):532-6. PubMed ID: 3887830
    [Abstract] [Full Text] [Related]

  • 4. Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice.
    Irwin N, McClean PL, O'Harte FP, Gault VA, Harriott P, Flatt PR.
    Diabetologia; 2007 Jul; 50(7):1532-40. PubMed ID: 17486314
    [Abstract] [Full Text] [Related]

  • 5. Immunoreactive C-peptide in spontaneous syndromes of obesity and diabetes in mice.
    Flatt PR, Bailey CJ, Hampton SM, Swanston-Flatt SK, Marks V.
    Horm Metab Res; 1987 Jan; 19(1):1-5. PubMed ID: 3549500
    [Abstract] [Full Text] [Related]

  • 6. Substance P, neurokinin A, vasoactive intestinal polypeptide and gastrin releasing peptide in the intestine and pancreas of spontaneously obese-diabetic mice.
    Bailey CJ, Flatt PR, Deacon CF, Shaw C, Conlon JM.
    Regul Pept; 1986 Dec 30; 16(3-4):339-48. PubMed ID: 2436255
    [Abstract] [Full Text] [Related]

  • 7. Attenuated secretion of glucose-dependent insulinotropic polypeptide (GIP) does not alleviate hyperphagic obesity and insulin resistance in ob/ob mice.
    Shimazu-Kuwahara S, Harada N, Yamane S, Joo E, Sankoda A, Kieffer TJ, Inagaki N.
    Mol Metab; 2017 Mar 30; 6(3):288-294. PubMed ID: 28271035
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cytochemical analysis of pancreatic islet hypercytolipidemia following diabetes (db/db) and obese (ob/ob) mutation expression: influence of genomic background.
    Garris DR, Garris BL.
    Pathobiology; 2004 Mar 30; 71(5):231-40. PubMed ID: 15459481
    [Abstract] [Full Text] [Related]

  • 10. Gastric inhibitory polypeptide and insulin responses to orally administered amino acids in genetically obese hyperglycemic (ob/ob) mice.
    Flatt PR, Kwasowski P, Howland RJ, Bailey CJ.
    J Nutr; 1991 Jul 30; 121(7):1123-8. PubMed ID: 2051232
    [Abstract] [Full Text] [Related]

  • 11. Gastric inhibitory polypeptide.
    Ebert R, Creutzfeldt W.
    Clin Gastroenterol; 1980 Sep 30; 9(3):679-98. PubMed ID: 6107191
    [Abstract] [Full Text] [Related]

  • 12. Temporal relationship of tissue somatostatin-like immunoreactivity to metabolic changes in genetically obese and diabetic mice.
    Berelowitz M, Coleman DL, Frohman LA.
    Diabetes; 1980 Sep 30; 29(9):717-23. PubMed ID: 6108273
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Morphometric analysis of obesity (ob/ob)- and diabetes (db/db)-associated hypothalamic neuronal degeneration in C57BL/KsJ mice.
    Garris DR.
    Brain Res; 1989 Oct 30; 501(1):162-70. PubMed ID: 2804691
    [Abstract] [Full Text] [Related]

  • 15. (Pro(3))GIP[mPEG]: novel, long-acting, mPEGylated antagonist of gastric inhibitory polypeptide for obesity-diabetes (diabesity) therapy.
    McClean PL, Irwin N, Hunter K, Gault VA, Flatt PR.
    Br J Pharmacol; 2008 Nov 30; 155(5):690-701. PubMed ID: 18695644
    [Abstract] [Full Text] [Related]

  • 16. The enteric enhancement of glucose-stimulated insulin release. The role of GIP in aging, obesity, and non-insulin-dependent diabetes mellitus.
    Elahi D, Andersen DK, Muller DC, Tobin JD, Brown JC, Andres R.
    Diabetes; 1984 Oct 30; 33(10):950-7. PubMed ID: 6383904
    [Abstract] [Full Text] [Related]

  • 17. Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin.
    Gault VA, O'Harte FP, Harriott P, Mooney MH, Green BD, Flatt PR.
    Diabetologia; 2003 Feb 30; 46(2):222-30. PubMed ID: 12627321
    [Abstract] [Full Text] [Related]

  • 18. Abnormally decreased NO and augmented CO production in islets of the leptin-deficient ob/ob mouse might contribute to explain hyperinsulinemia and islet survival in leptin-resistant type 2 obese diabetes.
    Jimenez-Feltstrom J, Salehi A, Meidute Abaraviciene S, Henningsson R, Lundquist I.
    Regul Pept; 2011 Oct 10; 170(1-3):43-51. PubMed ID: 21620903
    [Abstract] [Full Text] [Related]

  • 19. Enhanced cAMP generation and insulin-releasing potency of two novel Tyr1-modified enzyme-resistant forms of glucose-dependent insulinotropic polypeptide is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes.
    Gault VA, Flatt PR, Bailey CJ, Harriott P, Greer B, Mooney MH, O'harte FP.
    Biochem J; 2002 Nov 01; 367(Pt 3):913-20. PubMed ID: 12150711
    [Abstract] [Full Text] [Related]

  • 20. Oral glucose augmentation of insulin secretion. Interactions of gastric inhibitory polypeptide with ambient glucose and insulin levels.
    Andersen DK, Elahi D, Brown JC, Tobin JD, Andres R.
    J Clin Invest; 1978 Jul 01; 62(1):152-61. PubMed ID: 659629
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.